Oak Ridge Investments LLC Sells 862 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Oak Ridge Investments LLC lessened its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 4.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,895 shares of the biopharmaceutical company’s stock after selling 862 shares during the quarter. Oak Ridge Investments LLC’s holdings in Ultragenyx Pharmaceutical were worth $614,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Fred Alger Management LLC increased its stake in Ultragenyx Pharmaceutical by 12.5% during the 1st quarter. Fred Alger Management LLC now owns 524,637 shares of the biopharmaceutical company’s stock valued at $18,997,000 after purchasing an additional 58,372 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in Ultragenyx Pharmaceutical during the 2nd quarter valued at $353,000. Assenagon Asset Management S.A. grew its stake in shares of Ultragenyx Pharmaceutical by 439.0% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,163,755 shares of the biopharmaceutical company’s stock worth $42,314,000 after acquiring an additional 947,865 shares in the last quarter. Millennium Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 2.2% in the 1st quarter. Millennium Management LLC now owns 712,393 shares of the biopharmaceutical company’s stock worth $25,796,000 after acquiring an additional 15,157 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the 1st quarter worth $4,400,000. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

RARE opened at $31.45 on Monday. The firm has a market cap of $3.03 billion, a P/E ratio of -5.69 and a beta of 0.21. The firm has a 50-day moving average of $29.75 and a 200 day moving average of $32.98. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $25.81 and a fifty-two week high of $57.99.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.10. The company had revenue of $166.50 million during the quarter, compared to analyst estimates of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The firm’s revenue for the quarter was up 13.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on RARE. Morgan Stanley reduced their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, July 14th. Wells Fargo & Company reduced their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating for the company in a research note on Thursday, July 10th. Wedbush reduced their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating for the company in a research note on Monday, July 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group reduced their target price on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $81.50.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,450 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the transaction, the executive vice president owned 73,271 shares in the company, valued at $2,283,857.07. This trade represents a 3.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.50% of the stock is owned by corporate insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.